Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review

Overview

Journal J Ophthalmol

Publisher Wiley

Specialty Ophthalmology

Date 2018 Mar 27

PMID 29576875

Citations 18

Authors

Lei Lu

Ying Jiang

Ravindran Jaganathan

Yanli Hao

Affiliations

Soon will be listed here.

Abstract

Diabetic retinopathy (DR) is classically defined by its vascular lesions and damage in the neurons of the retina. The cellular and clinical elements of DR have many features of chronic inflammation. Understanding the individual cell-specific inflammatory changes in the retina may lead to novel therapeutic approaches to prevent vision loss. The systematic use of available pharmacotherapy has been reported as a useful adjunct tool to laser photocoagulation, a gold standard therapy for DR. Direct injections or intravitreal anti-inflammatory and antiangiogenesis agents are widely used pharmacotherapy to effectively treat DR and diabetic macular edema (DME). However, their effectiveness is short term, and the delivery system is often associated with adverse effects, such as cataract and increased intraocular pressure. Further, systemic agents (particularly hypoglycemic, hypolipidemic, and antihypertensive agents) and plants-based drugs have also provided promising treatment in the progression of DR. Recently, advancements in pluripotent stem cells technology enable restoration of retinal functionalities after transplantation of these cells into animals with retinal degeneration. This review paper summarizes the developments in the current and potential pharmacotherapy and therapeutic technology of DR. Literature search was done on online databases, PubMed, Google Scholar, clinitrials.gov, and browsing through individual ophthalmology journals and leading pharmaceutical company websites.

Citing Articles

Laser Treatment for Diabetic Retinopathy: History, Mechanism, and Novel Technologies.

Wang S, Hua R, Zhao Y, Liu L J Clin Med. 2024; 13(18).

PMID: 39336925 PMC: 11432231. DOI: 10.3390/jcm13185439.

Management of Microcomplications of Diabetes Mellitus: Challenges, Current Trends, and Future Perspectives in Treatment.

Yapislar H, Gurler E Biomedicines. 2024; 12(9).

PMID: 39335472 PMC: 11429415. DOI: 10.3390/biomedicines12091958.

Celecoxib/Cyclodextrin Eye Drop Microsuspensions: Evaluation of In Vitro Cytotoxicity and Anti-VEGF Efficacy for Retinal Diseases.

Jansook P, Soe H, Asasutjarit R, Tun T, Hnin H, Maw P Pharmaceutics. 2023; 15(12).

PMID: 38140030 PMC: 10748042. DOI: 10.3390/pharmaceutics15122689.

Laser Treatment Modalities for Diabetic Retinopathy.

Pande G, Tidake P Cureus. 2022; 14(10):e30024.

PMID: 36348830 PMC: 9637280. DOI: 10.7759/cureus.30024.

Inflammation in diabetic retinopathy: possible roles in pathogenesis and potential implications for therapy.

Tang L, Xu G, Zhang J Neural Regen Res. 2022; 18(5):976-982.

PMID: 36254977 PMC: 9827774. DOI: 10.4103/1673-5374.355743.

References

Brown D, Campochiaro P, Singh R, Li Z, Gray S, Saroj N . Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117(6):1124-1133.e1. DOI: 10.1016/j.ophtha.2010.02.022. View

Frank R, Keirn R, Kennedy A, Frank K . Galactose-induced retinal capillary basement membrane thickening: prevention by Sorbinil. Invest Ophthalmol Vis Sci. 1983; 24(11):1519-24. View

Vaajanen A, Lakkisto P, Virtanen I, Kankuri E, Oksala O, Vapaatalo H . Angiotensin receptors in the eyes of arterial hypertensive rats. Acta Ophthalmol. 2009; 88(4):431-8. DOI: 10.1111/j.1755-3768.2009.01563.x. View

Willis L, El-Remessy A, Somanath P, DeRemer D, Fagan S . Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence. Clin Sci (Lond). 2011; 120(8):307-19. DOI: 10.1042/cs20100389. View

Sakamoto T, Ishibashi T, Ogura Y, Shiraga F, Takeuchi S, Yamashita H . [Survey of triamcinolone-related non-infectious endophthalmitis]. Nippon Ganka Gakkai Zasshi. 2011; 115(6):523-8. View

Kim J, Lee B, Kim J, Yu Y, Kim M, Kim K . Rosmarinic acid suppresses retinal neovascularization via cell cycle arrest with increase of p21(WAF1) expression. Eur J Pharmacol. 2009; 615(1-3):150-4. DOI: 10.1016/j.ejphar.2009.05.015. View

Lin J, Bierhaus A, Bugert P, Dietrich N, Feng Y, vom Hagen F . Effect of R-(+)-alpha-lipoic acid on experimental diabetic retinopathy. Diabetologia. 2006; 49(5):1089-96. DOI: 10.1007/s00125-006-0174-y. View

Dehghan M, Ahmadieh H, Ramezani A, Entezari M, Anisian A . A randomized, placebo-controlled clinical trial of intravitreal triamcinolone for refractory diabetic macular edema. Int Ophthalmol. 2007; 28(1):7-17. DOI: 10.1007/s10792-007-9097-y. View

Yilmaz T, Weaver C, Gallagher M, Cordero-Coma M, Cervantes-Castaneda R, Klisovic D . Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology. 2009; 116(5):902-11. DOI: 10.1016/j.ophtha.2009.02.002. View

10.

Pearson R, Barber A, Rizzi M, Hippert C, Xue T, West E . Restoration of vision after transplantation of photoreceptors. Nature. 2012; 485(7396):99-103. PMC: 3888831. DOI: 10.1038/nature10997. View

11.

Kowluru R, Odenbach S . Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes. 2004; 53(12):3233-8. DOI: 10.2337/diabetes.53.12.3233. View

12.

Kuppermann B, Blumenkranz M, Haller J, Williams G, Weinberg D, Chou C . Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007; 125(3):309-17. DOI: 10.1001/archopht.125.3.309. View

13.

Haller J, Kuppermann B, Blumenkranz M, Williams G, Weinberg D, Chou C . Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010; 128(3):289-96. DOI: 10.1001/archophthalmol.2010.21. View

14.

Nguyen H, Li Y, Tsang S . Patient-Specific iPSC-Derived RPE for Modeling of Retinal Diseases. J Clin Med. 2015; 4(4):567-78. PMC: 4470156. DOI: 10.3390/jcm4040567. View

15.

Tucker B, Mullins R, Streb L, Anfinson K, Eyestone M, Kaalberg E . Patient-specific iPSC-derived photoreceptor precursor cells as a means to investigate retinitis pigmentosa. Elife. 2013; 2:e00824. PMC: 3755341. DOI: 10.7554/eLife.00824. View

16.

MacLaren R, Pearson R, MacNeil A, Douglas R, Salt T, Akimoto M . Retinal repair by transplantation of photoreceptor precursors. Nature. 2006; 444(7116):203-7. DOI: 10.1038/nature05161. View

17.

Vanore M, Mazzucato V, Siegel M . 'Left behind' but not left alone: parental migration & the psychosocial health of children in Moldova. Soc Sci Med. 2014; 132:252-60. DOI: 10.1016/j.socscimed.2014.08.040. View

18.

Sabu M, Smitha K, Kuttan R . Anti-diabetic activity of green tea polyphenols and their role in reducing oxidative stress in experimental diabetes. J Ethnopharmacol. 2002; 83(1-2):109-16. DOI: 10.1016/s0378-8741(02)00217-9. View

19.

Johnson T, Bull N, Hunt D, Marina N, Tomarev S, Martin K . Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma. Invest Ophthalmol Vis Sci. 2009; 51(4):2051-9. PMC: 2868400. DOI: 10.1167/iovs.09-4509. View

20.

Kumar B, Gupta S, Nag T, Srivastava S, Saxena R . Green tea prevents hyperglycemia-induced retinal oxidative stress and inflammation in streptozotocin-induced diabetic rats. Ophthalmic Res. 2011; 47(2):103-8. DOI: 10.1159/000330051. View